Community News

GPCR targets for an antibody therapeutics company

September 11, 2021

An early-stage biotechnology company with expertise in antibody therapeutics development is engaging BCBA to explore the GPCR-targeted therapeutics market. To that end, the BCBA project team will 1) conduct a comprehensive market landscape analysis of the GPCR therapeutic market to understand the market conditions and requirements for the development of compelling Proof-of-Concept (POC) programs in […]

Read More

Due diligence to guide venture capital investment

August 27, 2021

The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]

Read More

Strategic planning to increase awareness and adoption of Far-UVC light technology

June 12, 2021

An early-stage product company is developing smart solutions for whole-room health. The company has developed a light that emits in the far-UVC range, which has been shown to kill many pathogens and strongly indicated to be completely harmless to humans. This technology has the potential to revolutionize public health and greatly reduce the transmission of […]

Read More

Optimization of a direct-to-consumer test for the assessment of chronic inflammation

March 26, 2021

A direct-to-consumer (DTC) diagnostics company is developing a blood test panel for the assessment of chronic inflammation. Using a cutting-edge AI-based platform, the company is optimizing a panel that can provide their customers with deep insights on their inflammatory status with only a few drops of blood. Given the massive increase in DTC and telemedicine […]

Read More

Application prioritization for a next-generation antibody design and characterization platform

March 12, 2021

An early stage protein therapeutics company has developed a novel AI-driven platform for rapid, iterative antibody design and characterization and is in the process of prioritizing applications of their platform for a set of initial Proof of Concept (POC) programs. To that end, the BCBA project team will 1) evaluate the current research and framework […]

Read More

Market opportunity assessment for a high-throughput biologic manufacturing platform

February 19, 2021

An early-stage, global health focused platform company has developed methods to rapidly generate a variety of biologics inexpensively and in high throughput. The company is interested in understanding how to best position themselves in the market based on the competitive advantages that their platform provides. In particular, the company believes that the flexibility and rapid […]

Read More

Market opportunity assessment of novel bispecific antibodies for immuno-oncology

September 25, 2020

An early-stage therapeutics company is developing novel T-cell-engaging bispecific antibodies that enable targeted stimulation of the immune system to kill tumor cells.

Read More

Market opportunity assessment for a novel all-in-one NGS analysis library prep solution

July 7, 2020

The project team will analyze the market opportunity for a novel NGS library preparation kit for Illumina NGS systems that, in addition to primary sequence, captures long-range information enabling large structural variant detection and haplotype phasing along with 3D chromatin architecture.

Read More

Survey of disease indications for a comparative biology-based drug discovery platform

February 6, 2020

The BCBA project team will conduct a survey to evaluate and prioritize cardiovascular, metabolic, and neuro indications for an early stage company’s target discovery platform that leverages the power of comparative biology to develop therapeutics.

Read More

Prioritization of ocular indications for a novel gene editing platform

February 6, 2020

The multi-institutional project team will conduct a survey to evaluate and prioritize ocular indications for a venture-backed company’s novel gene editing platform.

Read More